Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
Status:
Recruiting
Trial end date:
2029-05-16
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with
early Alzheimer's Disease (AD) (including mild cognitive impairment [MCI] and mild dementia
due to AD) of 2 dose levels of GSK4527226 compared to placebo.